Literature DB >> 18980631

Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs.

Petra Bizikova1, Mark G Papich, Thierry Olivry.   

Abstract

Pharmacokinetic parameters of hydroxyzine and its active metabolite cetirizine were determined after oral and intravenous administration of 2 mg kg(-1) of hydroxyzine to six healthy dogs. Plasma drug levels were determined with high-pressure liquid chromatography. Pharmacodynamic studies evaluated the suppressive effect on histamine and anticanine IgE-mediated cutaneous wheal formation. Pharmacokinetic and pharmacodynamic correlations were determined with computer modelling. The mean systemic availability of oral hydroxyzine was 72%. Hydroxyzine was rapidly converted to cetirizine regardless of the route of administration. The mean area-under-the-curve was eight and ten times higher for cetirizine than hydroxyzine after intravenous and oral dosing, respectively. After oral administration of hydroxyzine, the mean peak concentration of cetirizine was approximately 2.2 microg mL(-1) and that of hydroxyzine 0.16 microg mL(-1). The terminal half-life for cetirizine varied between 10 and 11 h after intravenous and oral administration of hydroxyzine. A sigmoidal relationship was fit to the data comparing cetirizine plasma concentration to wheal suppression. Maximum inhibition (82% and 69% for histamine and anticanine IgE-mediated skin reactions, respectively) was observed during the first 8 h, which correlated with a plasma concentration of cetirizine greater than 1.5 microg mL(-1). Pharmacological modelling suggested that increasing either hydroxyzine dosages or frequencies of administration would not result in histamine inhibition superior to that obtained with twice daily hydroxyzine at 2 mg kg(-1). In conclusion, there was rapid conversion of hydroxyzine to cetirizine. The reduction of wheal formation appeared almost entirely due to cetirizine. Pharmacodynamic modelling predicted that maximal antihistamine effect would occur with twice daily oral administration of hydroxyzine at 2 mg kg(-1).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18980631     DOI: 10.1111/j.1365-3164.2008.00697.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  7 in total

1.  An open clinical trial on the efficacy of cetirizine hydrochloride in the management of allergic pruritus in cats.

Authors:  Joya S Griffin; Danny W Scott; William H Miller; Michelle M Tranchina
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

2.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

3.  Cetirizine per os: exposure and antihistamine effect in the dog.

Authors:  Carl Ekstrand; Carina Ingvast-Larsson; Ulf Bondesson; Mikael Hedeland; Lena Olsén
Journal:  Acta Vet Scand       Date:  2018-11-26       Impact factor: 1.695

Review 4.  Atopic dermatitis in cats and dogs: a difficult disease for animals and owners.

Authors:  Natalie Katharina Yvonne Gedon; Ralf Steffen Mueller
Journal:  Clin Transl Allergy       Date:  2018-10-05       Impact factor: 5.871

Review 5.  Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs.

Authors:  Vincent Bruet; Marion Mosca; Amaury Briand; Patrick Bourdeau; Didier Pin; Noëlle Cochet-Faivre; Marie-Christine Cadiergues
Journal:  Vet Sci       Date:  2022-03-22

6.  Stability, Permeability and Cytotoxicity of Buccal Films in Allergy Treatment.

Authors:  Krisztián Pamlényi; Géza Regdon; Dániel Nemes; Ferenc Fenyvesi; Ildikó Bácskay; Katalin Kristó
Journal:  Pharmaceutics       Date:  2022-08-05       Impact factor: 6.525

7.  Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial.

Authors:  Yun-Hsia Hsiao; Charles Chen; Ton Willemse
Journal:  J Vet Sci       Date:  2016-12-30       Impact factor: 1.672

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.